⚠ Evidence warning: Clinical trials or other evidence do not support the claim that quercetin and luteolin work as mast-cell stabilizers that are particularly useful in mast cell activation syndrome. This page keeps it as a report of what people, websites or other media say.

Hives and Flushing

Nuts, shrimp, eggs and sesame seeds on a dark surface
Foods involved in classic immunoglobulin E allergy include nuts, shellfish, eggs, milk, wheat and sesame
Infographic: acute versus chronic hives with trigger icons
Hives lasting less than six weeks are acute and usually triggered by a virus, food, drug or insect sting; longer-lasting forms are chronic
3D mast cell releasing glowing granules beside a blood vessel
Hives and flushing both arise when skin mast cells release histamine, tryptase, prostaglandin D2 and leukotrienes, widening blood vessels and causing itch

Table of Contents

  1. Overview
  2. Historical Background
  3. Types of Hives and Flushing
  4. Common Causes
  5. Mechanisms
  6. Evaluation
  7. Management
  8. When to Seek Medical Care
  9. Connections
  10. Key Research Papers
  11. Featured Videos

Overview

Hives (urticaria) are raised, itchy, blanching wheals that come and go, typically resolving within 24 hours at any given site. Flushing is transient redness and warmth, usually of the face, neck, and upper chest. Both arise from the release of histamine and other vasoactive mediators from skin mast cells. They share triggers and pathways, and frequently co-occur. Most acute cases are self-limited and viral or allergic; chronic forms (lasting more than six weeks) are more often autoimmune, mast-cell-mediated, or driven by physical triggers, and require systematic evaluation.

Historical Background

Urticaria has been recognized since Hippocrates as "knidosis," from the Greek for nettle. The discovery of histamine in 1910 and immunoglobulin E in 1966 established the basic mechanism. Chronic spontaneous urticaria as an autoimmune disease was characterized in the 1990s. Mast cell activation syndrome was formalized as a distinct clinical entity in 2010, and alpha-gal syndrome was identified after lone-star-tick exposures in the U.S. Southeast in 2009.

Types of Hives and Flushing

Common Causes

Mechanisms

Evaluation

Management

The 2026 international urticaria guideline (developed with 210 delegates from 107 societies in 59 countries; consensus conference December 2024) lays out a stepwise treatment algorithm: a second-generation H1 antihistamine at the standard dose, then up to four times that dose, then omalizumab. It describes dupilumab and remibrutinib as add-on treatments with phase 3 results, and keeps ciclosporin for severe disease that has not responded to licensed treatments. The guideline also states that omalizumab, dupilumab and remibrutinib are limited in practice by their high cost. It updates the 2018 and 2022 versions of the same guideline.

When to Seek Medical Care

Connections

Key Research Papers

  1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. — doi:10.1111/all.13397
  2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. — doi:10.1111/all.15090
  3. Zuberbier T, Ansari ZA, Abdul Latiff AH, et al. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy. 2026;81(8):2582-2632. — doi:10.1111/all.70210
  4. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. New England Journal of Medicine. 2013;368(10):924-935. — doi:10.1056/NEJMoa1215372
  5. Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. New England Journal of Medicine. 2025;392(10):984-994. — doi:10.1056/NEJMoa2408792
  6. Giménez-Arnau AM, Zharkov A, Yang B, et al. Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials. Journal of Allergy and Clinical Immunology: In Practice. 2026;14(8):1901-1913. — doi:10.1016/j.jaip.2026.05.027
  7. Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of Allergy and Clinical Immunology. 2024;154(1):184-194. — doi:10.1016/j.jaci.2024.01.028
  8. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. Journal of Allergy and Clinical Immunology. 2010;126(6):1099-1104. — doi:10.1016/j.jaci.2010.08.035
  9. Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1,3-galactose. Journal of Allergy and Clinical Immunology. 2009;123(2):426-433. — doi:10.1016/j.jaci.2008.10.052
  10. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(4):1125-1133. — doi:10.1016/j.jaip.2019.01.006
  11. Saini SS, Kaplan AP. Chronic spontaneous urticaria: the devil's itch. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1097-1106. — doi:10.1016/j.jaip.2018.04.013
  12. Khan DA. Chronic urticaria: diagnosis and management. Allergy and Asthma Proceedings. 2008;29(5):439-446. — doi:10.2500/aap.2008.29.3151
  13. Wilson JM, Schuyler AJ, Workman L, et al. Investigation into the α-Gal syndrome: characteristics of 261 children and adults reporting red meat allergy. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(7):2348-2358.e4. — doi:10.1016/j.jaip.2019.03.031
  14. Maintz L, Novak N. Histamine and histamine intolerance. American Journal of Clinical Nutrition. 2007;85(5):1185-1196. — doi:10.1093/ajcn/85.5.1185
  15. Izikson L, English JC III, Zirwas MJ. The flushing patient: differential diagnosis, workup, and treatment. Journal of the American Academy of Dermatology. 2006;55(2):193-208. — doi:10.1016/j.jaad.2005.07.057

PubMed Topic Searches

  1. PubMed: Chronic spontaneous urticaria
  2. PubMed: Mast cell activation syndrome diagnosis
  3. PubMed: Alpha-gal syndrome and meat allergy
  4. PubMed: Histamine intolerance and DAO deficiency
  5. PubMed: Omalizumab for chronic urticaria
  6. PubMed: Carcinoid syndrome flushing

Back to Table of Contents

Hives Flushing — scientific infographic poster